Torrent Pharmaceuticals' Q1 FY 2025-26 Quarterly Results
- 29 Jul 2025
Result Summary
- Torrent Pharmaceuticals Ltd reported a 13.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 8.9%.
- Its expenses for the quarter were up by 12.0% QoQ and 7.9% YoY.
- The net profit increased 22.0% QoQ and increased 19.9% YoY.
- The earnings per share (EPS) of Torrent Pharmaceuticals Ltd stood at 16.2 during Q1 FY 2025-26.
Financial Statments for Q1 FY 2025-26
| (₹ crores) | Q1FY26 | Q4FY25 | Q1FY25 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 3141.00 | 2776.00 | 2883.00 | 13.1% | 8.9% |
Total Expenses | 2403.00 | 2145.00 | 2227.00 | 12.0% | 7.9% |
Profit Before Tax | 738.00 | 631.00 | 656.00 | 17.0% | 12.5% |
Tax | 190.00 | 182.00 | 199.00 | 4.4% | -4.5% |
Profit After Tax | 548.00 | 449.00 | 457.00 | 22.0% | 19.9% |
Earnings Per Share | 16.20 | 13.30 | 13.50 | 21.8% | 20.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Torrent Pharmaceuticals Ltd is a leading pharmaceutical company based in India. It is primarily engaged in the development, manufacturing, and marketing of pharmaceutical products. The company operates in the healthcare sector, offering a range of therapeutic products. Torrent Pharmaceuticals is known for its focus on research and development, aiming to deliver high-quality generic and branded pharmaceutical products globally. The company has a significant presence in both domestic and international markets, with a portfolio that includes cardiovascular, central nervous system, gastrointestinal, and anti-infective medications. Recent developments in the company are not specified in the provided data.
Revenue
In the first quarter of the fiscal year 2026 (Q1FY26), Torrent Pharmaceuticals Ltd reported a total income of ₹3,141.00 crores, reflecting a quarter-over-quarter (QoQ) increase of 13.1% from ₹2,776.00 crores in Q4FY25. Compared to the same quarter in the previous year (Q1FY25), where the total income was ₹2,883.00 crores, the year-over-year (YoY) growth is 8.9%. This data indicates a positive trend in the company's revenue generation over both quarterly and yearly periods, demonstrating the company's ability to enhance its income stream.
Profitability
The profit before tax for Q1FY26 stood at ₹738.00 crores, showing a QoQ growth of 17.0% from ₹631.00 crores in Q4FY25. When compared to Q1FY25, the YoY increase is 12.5% from ₹656.00 crores. The tax expense for Q1FY26 was ₹190.00 crores, which is a 4.4% increase QoQ from ₹182.00 crores in Q4FY25, but a YoY decrease of 4.5% from ₹199.00 crores in Q1FY25. Consequently, the profit after tax for Q1FY26 was ₹548.00 crores, marking a 22.0% QoQ rise from ₹449.00 crores in Q4FY25 and a 19.9% YoY rise from ₹457.00 crores in Q1FY25. The earnings per share (EPS) also increased to ₹16.20 in Q1FY26, compared to ₹13.30 in Q4FY25 and ₹13.50 in Q1FY25, representing a QoQ increase of 21.8% and a YoY increase of 20.0%.
Operating Metrics
The total expenses for Torrent Pharmaceuticals in Q1FY26 were ₹2,403.00 crores, which reflects a 12.0% increase QoQ from ₹2,145.00 crores in Q4FY25. Compared to Q1FY25, where the expenses were ₹2,227.00 crores, there is a YoY increase of 7.9%. This data indicates that while expenses have increased, the rate of increase in total income has outpaced the increase in total expenses. An analysis of financial ratios such as the P/E ratio, debt-to-equity ratio, or current ratio would require additional data not provided in the dataset.
FAQs
When was Torrent Pharmaceuticals Ltd Q1 FY 2025-26 result announced?
Torrent Pharmaceuticals Ltd announced its Q1 FY 2025-26 results on 14 August, 2025.
What are Torrent Pharmaceuticals Ltd quarterly results?
Torrent Pharmaceuticals Ltd quarterly results refer to the company’s financial performance over a three-month period, including key metrics like revenue, net profit, earnings per share (EPS), and margin performance.
What were the key highlights of Torrent Pharmaceuticals Ltd Q1 FY 2025-26 results?
Key highlights of Torrent Pharmaceuticals Ltd Q1 FY 2025-26 results include:
- Revenue: ₹3141.00 crore
- Net Profit: ₹548.00 crore
- EBITDA: ₹995.00 crore
- Year-over-Year Growth: 8.9%
- Quarter-over-Quarter Growth: 13.1%
How did Torrent Pharmaceuticals Ltd net profit perform in this quarter?
Torrent Pharmaceuticals Ltd reported a net profit of ₹548.00 crore in Q1 FY 2025-26, reflecting a 19.9% year-over-year growth.
What was Torrent Pharmaceuticals Ltd revenue in Q1 FY 2025-26?
Torrent Pharmaceuticals Ltd posted a revenue of ₹3141.00 crore in Q1 FY 2025-26.